Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
The three approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including abemaciclib, have shown differences in their preclinical, pharmacological, and clinical data. Abemaciclib stands out for its broader target range and more rapid and intense activity. It has demonstrated efficacy as a monot...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/18/4452 |
| _version_ | 1797580923935391744 |
|---|---|
| author | Alicia Milagros de Luna Aguilar Javier David Benitez Fuentes Justo Ortega Anselmi Jennifer Olalla Inoa Paloma Flores Navarro Alfonso Lopez de Sá Jesus Fuentes Antras Cristina Rodríguez Rey Aída Ortega Candil Fernando Moreno Antón Jose Ángel García Sáenz |
| author_facet | Alicia Milagros de Luna Aguilar Javier David Benitez Fuentes Justo Ortega Anselmi Jennifer Olalla Inoa Paloma Flores Navarro Alfonso Lopez de Sá Jesus Fuentes Antras Cristina Rodríguez Rey Aída Ortega Candil Fernando Moreno Antón Jose Ángel García Sáenz |
| author_sort | Alicia Milagros de Luna Aguilar |
| collection | DOAJ |
| description | The three approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including abemaciclib, have shown differences in their preclinical, pharmacological, and clinical data. Abemaciclib stands out for its broader target range and more rapid and intense activity. It has demonstrated efficacy as a monotherapy or in combination with tamoxifen in endocrine-refractory metastatic breast cancer (MBC) patients with prior chemotherapy. However, the clinical data on abemaciclib after exposure to previous CDK4/6 inhibitors are limited. In this single-center retrospective case series, we identified all patients who received abemaciclib until February 2022 after experiencing documented progression on palbociclib or ribociclib. The safety profile and clinical outcomes of abemaciclib treatment in this specific patient cohort were evaluated. Eleven patients were included in this retrospective case series, nine receiving abemaciclib with tamoxifen. Eight patients had visceral involvement, and the median age was 69 (ranging from 42 to 84). The median time from the end of prior CDK4/6 inhibitor treatment to abemaciclib initiation was 17.5 months (ranging from 3 to 41 months). Patients had undergone a median of three prior therapies (ranging from 1 to 7), including chemotherapy in 54.5% of cases. The median follow-up time was six months (ranging from 1 to 22 months). The median progression-free survival (PFS) was 8 months (95% CI 3.9–12). Five patients continued abemaciclib treatment, and one patient with liver metastases achieved a complete hepatic response. The most common adverse events were diarrhea (72.7%, no grade ≥ 3) and asthenia (27.3%, no grade ≥ 3). Our preliminary findings suggest that abemaciclib could be an effective and safe treatment option for MBC patients who have previously received palbociclib or ribociclib. |
| first_indexed | 2024-03-10T22:56:57Z |
| format | Article |
| id | doaj.art-209c48fdd38d4641a2d64fb6fbe5aced |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T22:56:57Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-209c48fdd38d4641a2d64fb6fbe5aced2023-11-19T09:54:00ZengMDPI AGCancers2072-66942023-09-011518445210.3390/cancers15184452Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series StudyAlicia Milagros de Luna Aguilar0Javier David Benitez Fuentes1Justo Ortega Anselmi2Jennifer Olalla Inoa3Paloma Flores Navarro4Alfonso Lopez de Sá5Jesus Fuentes Antras6Cristina Rodríguez Rey7Aída Ortega Candil8Fernando Moreno Antón9Jose Ángel García Sáenz10Department of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Nuclear Medicine, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Nuclear Medicine, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainDepartment of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, S/N, 28040 Madrid, SpainThe three approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including abemaciclib, have shown differences in their preclinical, pharmacological, and clinical data. Abemaciclib stands out for its broader target range and more rapid and intense activity. It has demonstrated efficacy as a monotherapy or in combination with tamoxifen in endocrine-refractory metastatic breast cancer (MBC) patients with prior chemotherapy. However, the clinical data on abemaciclib after exposure to previous CDK4/6 inhibitors are limited. In this single-center retrospective case series, we identified all patients who received abemaciclib until February 2022 after experiencing documented progression on palbociclib or ribociclib. The safety profile and clinical outcomes of abemaciclib treatment in this specific patient cohort were evaluated. Eleven patients were included in this retrospective case series, nine receiving abemaciclib with tamoxifen. Eight patients had visceral involvement, and the median age was 69 (ranging from 42 to 84). The median time from the end of prior CDK4/6 inhibitor treatment to abemaciclib initiation was 17.5 months (ranging from 3 to 41 months). Patients had undergone a median of three prior therapies (ranging from 1 to 7), including chemotherapy in 54.5% of cases. The median follow-up time was six months (ranging from 1 to 22 months). The median progression-free survival (PFS) was 8 months (95% CI 3.9–12). Five patients continued abemaciclib treatment, and one patient with liver metastases achieved a complete hepatic response. The most common adverse events were diarrhea (72.7%, no grade ≥ 3) and asthenia (27.3%, no grade ≥ 3). Our preliminary findings suggest that abemaciclib could be an effective and safe treatment option for MBC patients who have previously received palbociclib or ribociclib.https://www.mdpi.com/2072-6694/15/18/4452metastatic breast cancercontinuing CDK4/6 inhibitionabemaciclibendocrine therapyrechallenge |
| spellingShingle | Alicia Milagros de Luna Aguilar Javier David Benitez Fuentes Justo Ortega Anselmi Jennifer Olalla Inoa Paloma Flores Navarro Alfonso Lopez de Sá Jesus Fuentes Antras Cristina Rodríguez Rey Aída Ortega Candil Fernando Moreno Antón Jose Ángel García Sáenz Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study Cancers metastatic breast cancer continuing CDK4/6 inhibition abemaciclib endocrine therapy rechallenge |
| title | Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study |
| title_full | Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study |
| title_fullStr | Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study |
| title_full_unstemmed | Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study |
| title_short | Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study |
| title_sort | clinical experience with abemaciclib in patients previously treated with another cdk 4 6 inhibitor in a tertiary hospital a case series study |
| topic | metastatic breast cancer continuing CDK4/6 inhibition abemaciclib endocrine therapy rechallenge |
| url | https://www.mdpi.com/2072-6694/15/18/4452 |
| work_keys_str_mv | AT aliciamilagrosdelunaaguilar clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT javierdavidbenitezfuentes clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT justoortegaanselmi clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT jenniferolallainoa clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT palomafloresnavarro clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT alfonsolopezdesa clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT jesusfuentesantras clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT cristinarodriguezrey clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT aidaortegacandil clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT fernandomorenoanton clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy AT joseangelgarciasaenz clinicalexperiencewithabemaciclibinpatientspreviouslytreatedwithanothercdk46inhibitorinatertiaryhospitalacaseseriesstudy |